Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells

Blood

Volumn 105, Issue 10, 2005, Pages 3951-3955

  Lee, Young Ran ^b   Yang, In Ho ^b   Lee, Young Hee ^b   Sun Alm, ^b   Song, Sukgil ^b   Li, Hong ^b   Han, Kun ^b   Kim, Kyungjae ^b   Eo, Seong Kug ^b   Lee, Chong Kil ^a  

^a Chungbuk National University   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; PEPTIDE; RAPAMYCIN; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MICROENCAPSULATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 20844453233     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-3927     Document Type: Article

References (29)

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
2. Harding CV. Phagocytic processing of antigens for presentation by MHC molecules. Trends Cell Biol. 1995;5:105-108.
3. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143:1283-1288.
4. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47-64.
5. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965.
6. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-hematopoietic cells requires presentation of exogenous antigen. Nature. 1999;398:77-80.
7. Sigal L, Rock KL. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to virus and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J Exp Med. 2000;192:1143-1150.
8. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacological probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519-560.
9. Friedman J, Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA. Cell. 1991;66:799-806.
10. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK-506 complexes. Cell. 1991;66:807-815.
11. Bierer B, Mattila P, Standaert R, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990;87:9231-9235.
12. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996;14:483-510.
13. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 1977;158:2723-2730.
14. Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci U S A. 1992;89:6020-6024.
15. Porgador A, Yewdell JW1 Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using monoclonal antibody. Immunity. 1997;6:715-726.
16. Lee JK, Lee MK, Yun Y-P, et al. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int Immunopharmacol. 2001;1:1275-1284.
17. Man K, Lee K-D, Gao Z-G, Park J-S. Preparation and evaluation of poly(L-lactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J Control Release. 2001;75:259-269.
18. + cell help. J Exp Med. 1997;186:65-70.
19. + T cells: cross-priming in infectious diseases. Curr Opin Immunol. 2001;13:437-441.
20. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol. 2000;30:1807-1812.
21. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med. 2001;49:442-449.
22. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation. 1999;68:1255-1263.
23. Salgado CG, Nakamura G, Sugaya M, et al. Differential effects of cytokines and immunosuppressive drugs on CD40, B7-1, and B7-2 expression on purified epidermal Langerhans cells. J Invest Dermatol. 1999;113:1021-1027.
24. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood. 2002;100:1084-1087.
25. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation. 2003;75:137-145.
26. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol. 2001;166:6099-6103.
27. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath W. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today. 1998;19:368-373.
28. Cuba M, von Breitenburg P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
29. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77:1319-1326.